| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1031949315 |
| P356 | DOI | 10.1385/NCC:5:1:71 |
| P698 | PubMed publication ID | 16960300 |
| P2093 | author name string | Junling Gao | |
| Daniel T Laskowitz | |||
| David S Warner | |||
| Huaxin Sheng | |||
| John R Lynch | |||
| David L McDonagh | |||
| Haichen Wang | |||
| Timothy F Lassiter | |||
| P2860 | cites work | Effects of levetiracetam on the production of nitric oxide--an in vivo study | Q45292920 |
| Potential effects of common drugs on stroke recovery | Q48482996 | ||
| A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury | Q49071765 | ||
| EPILEPSY AFTER RUPTURED INTRACRANIAL ANEURYSM. | Q50285041 | ||
| Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. | Q50900490 | ||
| Epileptic seizures after subarachnoid hemorrhage. | Q51053340 | ||
| A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels | Q69851259 | ||
| Phenytoin-induced thrombocytopenia | Q73217810 | ||
| Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin | Q73344084 | ||
| Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage | Q73826660 | ||
| Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage | Q74047731 | ||
| Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis | Q74460331 | ||
| Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema | Q77466577 | ||
| A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage | Q82648185 | ||
| The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam | Q24561949 | ||
| Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) | Q24655420 | ||
| The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents | Q30498688 | ||
| Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials | Q30986943 | ||
| Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Panel on Nonemergency Use of Parenteral Phenytoin Products | Q33794387 | ||
| Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration | Q33915341 | ||
| Levetiracetam. A review of its adjunctive use in the management of partial onset seizures | Q34086045 | ||
| A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures | Q34155061 | ||
| Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology | Q34170263 | ||
| Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage | Q34386555 | ||
| Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs | Q35183961 | ||
| Levetiracetam safety profiles and tolerability in epilepsy patients. | Q35873716 | ||
| Dilantin hypersensitivity reaction. | Q40670245 | ||
| Intravenous administration of fosphenytoin: options for the management of seizures | Q40997741 | ||
| Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction | Q42198583 | ||
| Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy | Q42539954 | ||
| Reversal of cerebral vasospasm using an intrathecally administered nitric oxide donor | Q42540664 | ||
| Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia | Q43683385 | ||
| Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage | Q44240509 | ||
| Expression of brain-derived neurotrophic factor (BDNF) and inducible nitric oxide synthase (iNOS) in rat astrocyte cultures treated with Levetiracetam. | Q44451294 | ||
| Psychiatric adverse events during levetiracetam therapy | Q44578346 | ||
| A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics | Q45091283 | ||
| A new model of diffuse brain injury in rats. Part II: Morphological characterization | Q45091286 | ||
| P433 | issue | 1 | |
| P921 | main subject | (S)-etiracetam | Q417227 |
| murine model | Q122890741 | ||
| P304 | page(s) | 71-78 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Neurocritical Care | Q15745303 |
| P1476 | title | Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage | |
| P478 | volume | 5 |
| Q39123432 | Abbreviated levetiracetam treatment effects on behavioural and histological outcomes after experimental TBI. |
| Q64120494 | An experimental study on the early diagnosis of traumatic brain injury in rabbits based on a noncontact and portable system |
| Q28315817 | CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice |
| Q37865100 | Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage. |
| Q84965433 | Dose-dependent ultrastructural and morphometric alterations after erythropoietin treatment in rat femoral artery vasospasm model |
| Q36640693 | Effects of Different Doses of Levetiracetam on Aquaporin 4 Expression in Rats with Brain Edema Following Fluid Percussion Injury |
| Q33634989 | Female gonadal hormone effects on microglial activation and functional outcomes in a mouse model of moderate traumatic brain injury |
| Q28537667 | Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy |
| Q48239099 | Lacosamide improves outcome in a murine model of traumatic brain injury |
| Q41910193 | Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study. |
| Q33761706 | Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. |
| Q37688063 | Levetiracetam: a comprehensive review |
| Q31110554 | Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. |
| Q38244403 | Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury |
| Q37209019 | Management of post-subarachnoid hemorrhage vasospasm |
| Q64055514 | Neurobehavioral Deficits After Subarachnoid Hemorrhage in Mice: Sensitivity Analysis and Development of a New Composite Score |
| Q26830325 | Neurobehavioral effects of levetiracetam in patients with traumatic brain injury |
| Q33496591 | Neurological and neurobehavioral assessment of experimental subarachnoid hemorrhage |
| Q48896314 | Neuroprotection and anti-seizure effects of levetiracetam in a rat model of penetrating ballistic-like brain injury |
| Q38684428 | Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs |
| Q36034824 | Neuroprotection in subarachnoid hemorrhage |
| Q50736416 | Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury. |
| Q48067659 | Opposing effects of traumatic brain injury on excitatory synaptic function in the lateral amygdala in the absence and presence of preinjury stress |
| Q83862861 | Optimal antiepileptic drug use for patients with subarachnoid hemorrhage |
| Q36060634 | Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature |
| Q27004055 | Post-traumatic epilepsy: current and emerging treatment options |
| Q89164767 | Prophylactic Seizure Medication and Health-Related Quality of Life After Intracerebral Hemorrhage |
| Q37276387 | Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke |
| Q38166331 | Seizure prophylaxis in neurocritical care: a review of evidence-based support. |
| Q38047704 | Seizures after aneurysmal subarachnoid hemorrhage: a systematic review of outcomes |
| Q37374151 | Statins in traumatic brain injury |
| Q37985377 | Status epilepticus: a review, with emphasis on refractory cases. |
| Q47417746 | The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum |
| Q28535091 | The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion |
| Q37287407 | Towards clinical management of traumatic brain injury: a review of models and mechanisms from a biomechanical perspective |
| Q84975640 | Traumatic Brain Injury Exacerbates Neurodegenerative Pathology: Improvement with an Apolipoprotein E-Based Therapeutic |
Search more.